These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21478328)

  • 41. Effect of alfacalcidol on cardiac function in patients with chronic kidney disease stage 4 and secondary hyperparathyroidism: a pilot study.
    Ivarsen P; Povlsen JV; Christensen KL
    Scand J Urol Nephrol; 2012 Oct; 46(5):381-8. PubMed ID: 22724916
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vitamin D receptor activation reduces inflammatory cytokines and plasma MicroRNAs in moderate chronic kidney disease - a randomized trial.
    Mansouri L; Lundwall K; Moshfegh A; Jacobson SH; Lundahl J; Spaak J
    BMC Nephrol; 2017 May; 18(1):161. PubMed ID: 28511692
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.
    Goldenberg MM
    Clin Ther; 1999 Mar; 21(3):432-41. PubMed ID: 10321413
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Follow up after sample size re-estimation in a breast cancer randomized trial for disease-free survival.
    Hade EM; Young GS; Love RR
    Trials; 2019 Aug; 20(1):527. PubMed ID: 31443726
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vitamin D receptor agonist VS-105 improves cardiac function in the presence of enalapril in 5/6 nephrectomized rats.
    Wu-Wong JR; Chen YW; Wessale JL
    Am J Physiol Renal Physiol; 2015 Feb; 308(4):F309-19. PubMed ID: 25503724
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
    Coyne D; Acharya M; Qiu P; Abboud H; Batlle D; Rosansky S; Fadem S; Levine B; Williams L; Andress DL; Sprague SM
    Am J Kidney Dis; 2006 Feb; 47(2):263-76. PubMed ID: 16431255
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial.
    Axelsson A; Iversen K; Vejlstrup N; Ho C; Norsk J; Langhoff L; Ahtarovski K; Corell P; Havndrup O; Jensen M; Bundgaard H
    Lancet Diabetes Endocrinol; 2015 Feb; 3(2):123-31. PubMed ID: 25533774
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
    Lindberg J; Martin KJ; González EA; Acchiardo SR; Valdin JR; Soltanek C
    Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Paricalcitol reduces proteinuria but does not modify peritoneal protein loss in patients on peritoneal dialysis.
    Sánchez-Álvarez JE; Rodríguez-Suárez C; Coronel-Aguilar D; González-Díaz I; Núñez-Moral M; Peláez-Requejo B; Fernández-Viña A; Quintana-Fernández A
    Nefrologia; 2013 Jan; 33(1):70-6. PubMed ID: 23364628
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients.
    Massimetti C; Pontillo D; Feriozzi S; Costantini S; Capezzuto A; Ancarani E
    Blood Purif; 1998; 16(6):317-24. PubMed ID: 10343078
    [TBL] [Abstract][Full Text] [Related]  

  • 51. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey.
    Cozzolino M; Brancaccio D; Cannella G; Messa P; Gesualdo L; Marangella M; LoDeserto C; Pozzato M; Rombolà G; Costanzo AM; di Luzio Paparatti U; Mazzaferro S;
    Nephrol Dial Transplant; 2012 Sep; 27(9):3588-94. PubMed ID: 22523119
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
    Ong LM; Narayanan P; Goh HK; Manocha AB; Ghazali A; Omar M; Mohamad S; Goh BL; Shah S; Seman MR; Vaithilingam I; Ghazalli R; Rahmat K; Shaariah W; Ching CH;
    Nephrology (Carlton); 2013 Mar; 18(3):194-200. PubMed ID: 23311404
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
    Sharma A; Ketteler M; Marshall TS; Khan SS; Schumock GT
    J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reply to "The role of fibroblast growth factor-23 in left atrial volume".
    Tamez H; Andress D; Solomon SD; Thadhani R
    Am Heart J; 2013 May; 165(5):e23. PubMed ID: 23622924
    [No Abstract]   [Full Text] [Related]  

  • 55. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.
    Teng M; Wolf M; Lowrie E; Ofsthun N; Lazarus JM; Thadhani R
    N Engl J Med; 2003 Jul; 349(5):446-56. PubMed ID: 12890843
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vitamin D therapy and cardiac function in chronic kidney disease.
    Slatopolsky E
    JAMA; 2012 Jun; 307(21):2254; author reply 2254-5. PubMed ID: 22706822
    [No Abstract]   [Full Text] [Related]  

  • 58. Vitamin D therapy and cardiac function in chronic kidney disease.
    Rajagopalan S; Chan CT
    JAMA; 2012 Jun; 307(21):2253; author reply 2254. PubMed ID: 22706820
    [No Abstract]   [Full Text] [Related]  

  • 59. Vitamin D therapy and cardiac function in chronic kidney disease.
    Fourtounas C
    JAMA; 2012 Jun; 307(21):2253; author reply 2254. PubMed ID: 22706819
    [No Abstract]   [Full Text] [Related]  

  • 60. Sample size re-estimation incorporating prior information on a nuisance parameter.
    Mütze T; Schmidli H; Friede T
    Pharm Stat; 2018 Mar; 17(2):126-143. PubMed ID: 29181869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.